---
title: ADC (Antibody-Drug Conjugate) Manufacturing CDMOs in Asia-Pacific
path: /services/adc-manufacturing/apac
companies_count: 13
---

# ADC (Antibody-Drug Conjugate) Manufacturing CDMOs in Asia-Pacific

13 published CDMOs match ADC (Antibody-Drug Conjugate) Manufacturing in Asia-Pacific.

Locations in this set include United States, China, India, United Kingdom, Japan, and France.

Capabilities that show up most often in this set: Antibody-Drug Conjugate (ADC), Biologics (Other), Small Molecule, Biologics (Monoclonal Antibodies), and Peptide.

## Matching companies

- [AGC Biologics](/companies/agcbio)
  - Global CDMO offering development and manufacturing for protein expression biologics, pDNA, mRNA, viral vectors (AAV, LVV, RVV), and genetically engineered cells with scale-out manufacturing capabilities.
- [Ajinomoto Bio-Pharma Services](/companies/ajibio-pharma)
  - Ajinomoto Bio-Pharma Services is a global contract development and manufacturing organization (CDMO) dedicated to improving the health of humankind through adaptive solutions and responsive service.
- [Altruist Biologics](/companies/altruist-biologics)
  - Global CDMO offering end-to-end development and GMP manufacturing for monoclonal antibodies, bispecific antibodies, fusion proteins, recombinant proteins, and antibody-drug conjugates, with facilities in Suzhou and Hangzhou featuring up to 20,000-liter bioreactors.
- [Axplora](/companies/axplora)
  - Global CDMO and API manufacturer specializing in complex small molecule development, ADC manufacturing, HPAPIs, and hazardous chemistry across ten production sites in Europe, India, and the US.
- [Carbogen Amcis](/companies/carbogen-amcis)
  - Full-service CDMO offering integrated drug substance and sterile drug product development and manufacturing from early phase through commercialization, with specialized capabilities in API synthesis, process development, analytical services, and stability testing across multiple scales.
- [IDT Australia](/companies/idtaus-com)
  - IDT Australia is a cGMP CDMO delivering end-to-end pharmaceutical development and manufacturing services from active pharmaceutical ingredients to finished dosage forms, with expertise in small molecule APIs, specialty orals, advanced therapies, and integrated regulatory support.
- [Pharmaron](/companies/pharmaron)
  - Premier life science CRO and CDMO offering integrated R&D and manufacturing across drug discovery, preclinical, clinical development, and commercialization for small molecules, biologics, and cell & gene therapies. 25,000+ employees across China, US, and UK.
- [Piramal Pharma Solutions](/companies/piramalpharmasolutions)
  - CDMO specializing in HPAPIs, ADCs, peptides, vaccines, and biologics with 4,700+ team members across 15 global sites and 500+ customers. Offers integrated development and manufacturing with backward integration capabilities and global program management.
- [Porton](/companies/portonpharma)
  - Porton is a global CDMO offering integrated manufacturing and development services across small molecules, peptides, oligonucleotides, biologics, and conjugates with specialized capabilities in flow chemistry, biocatalysis, and advanced therapies.
- [Sai Life Sciences](/companies/sailife)
  - Integrated CRDMO offering discovery, development, and manufacturing services for small molecule NCE programs across 280+ global pharma and biotech clients.
- [Samsung Biologics](/companies/samsungbiologics)
  - Leading CDMO offering end-to-end biologics development and manufacturing from cell line development through aseptic fill-finish, with capabilities in drug substance, drug product, ADC, and mRNA services.
- [Syngene International](/companies/syngeneintl)
  - Innovation-led CRDMO offering integrated scientific services from early discovery through commercial manufacturing, with cGMP-compliant facilities, 5,200+ scientists, and a new 50,000-liter single-use bioreactor capacity in the U.S.
- [WuXi XDC](/companies/wuxi-xdc)
  - WuXi XDC is a leading CRDMO offering integrated discovery, development, and cGMP manufacturing services for antibody drug conjugates (ADCs) and bioconjugates, with proximately located facilities that reduce development timelines and costs.